Engineered Tissue Treg Therapy for ALS (ALS)
Official title: Engineered Tissue Treg Therapy for the Treatment of ALS
Funded at Gentibio, INC. · NIH-11405442 · Data updated 2026-11-12
A new, patient-focused therapy using engineered immune cells (Tregs) to reduce brain inflammation and slow ALS progression.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Gentibio, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | September 7, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $320,037 |
| NIH project number | 1R43NS149828-01 |
| Project ID | NIH-11405442 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults diagnosed with ALS who meet study-specific criteria and can participate in cell-based therapy research.
✕Less likely to help
People not eligible for cell-based therapies or those with advanced disease or specific medical contraindications may not benefit.
What this research studies
This project tests engineered regulatory T cells designed to home to inflamed nervous tissue and support healing in people with ALS. Researchers will study how these cells behave under ALS-like conditions and how they interact with immune cells from ALS patients. The study aims to identify biomarkers and mechanisms that show whether these cells can safely persist and function in the ALS environment.
Why it matters
Potential benefit: If successful, this therapy could become a new way to reduce inflammation and slow decline in ALS.
How similar studies have gone: Other ALS-related immune approaches have shown promise in preclinical models, with early human data suggesting potential benefit.
Where this research is happening
-
Gentibio, INC.
Cambridge, United States Active
Researchers
- Principal investigator: Zammit, Nathan William — Gentibio, INC.
- Study coordinator: Zammit, Nathan William
Related research
Other NIH-funded projects on the same topics.
-
GNTI-148: an off-the-shelf engineered regulatory T cell therapy for new-onset type 1 diabetes
A new, ready-to-use cell therapy derived from donor cells aims to restore immune tolerance and protect insulin-producing cells in people newly diagnosed with type 1 diabetes.
-
Engineered tissue regulatory T cells as a treatment for stroke
A new off-the-shelf cell therapy using engineered regulatory T cells could help people who have an ischemic stroke recover by reducing inflammation and promoting tissue repair.
-
Engineered gut-targeted regulatory T cells for inflammatory bowel disease
A new allogeneic, gut-focused cell therapy using engineered regulatory T cells to help people with inflammatory bowel disease feel better and stay in remission.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.